Structure via PubChem · Public domain (PubChem)
PF-592379
Sign in to saveAlso known as PF-592,379
PF-592379 is a drug developed by Pfizer which acts as a potent, selective and orally active agonist for the dopamine D3 receptor, which was under development as a potential medication for the treatment of female sexual dysfunction and male erectile dysfunction but was never marketed. Unlike some other less selective D3 agonists, a research study showed that PF-592379 has little misuse potential in animal studies, and so was selected for further development and potentially human clinical trials. Development has since been discontinued.
Chemical data
- Formula
- C13H21N3O
- Molecular weight
- 235.33 g/mol
- IUPAC name
- 5-[(2R,5S)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine
- SMILES
- CCCN1C[C@H](OC[C@@H]1C)C2=CN=C(C=C2)N
- InChIKey
- DFTCYTDJDXZFSK-JQWIXIFHSA-N
- XLogP
- 1.3
- Polar surface area
- 51.4 Ų
- H-bond donors
- 1
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 235.168462
Show 4 more facts
- chemical formula
- C₁₃H₂₁N₃O
- isomeric SMILES
- CCCN1C[C@H](OC[C@@H]1C)C2=CN=C(C=C2)N
- canonical SMILES
- CCCN1CC(OCC1C)C2=CN=C(C=C2)N
- Commons category
- PF-592,379
Sources (1)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
PF-592379 is a drug developed by Pfizer which acts as a potent, selective and orally active agonist for the dopamine D3 receptor, which was under development as a potential medication for the treatment of female sexual dysfunction and male erectile dysfunction but was never marketed. Unlike some other less selective D3 agonists, a research study showed that PF-592379 has little misuse potential in animal studies, and so was selected for further development and potentially human clinical trials. Development has since been discontinued.
== See also == List of investigational sexual dysfunction drugs 7-OH-DPAT PD-128,907 PF-219,061
Excerpted from Wikipedia’s “PF-592379” article, available under the CC BY-SA 4.0 licence.